IN2014DN09346A - - Google Patents

Info

Publication number
IN2014DN09346A
IN2014DN09346A IN9346DEN2014A IN2014DN09346A IN 2014DN09346 A IN2014DN09346 A IN 2014DN09346A IN 9346DEN2014 A IN9346DEN2014 A IN 9346DEN2014A IN 2014DN09346 A IN2014DN09346 A IN 2014DN09346A
Authority
IN
India
Prior art keywords
compounds
methods
general formula
provides novel
compositions including
Prior art date
Application number
Other languages
English (en)
Inventor
Daniel Hunziker
Patrizio Mattei
Harald Mauser
Marco Prunotto
Christoph Ullmer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2014DN09346A publication Critical patent/IN2014DN09346A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN9346DEN2014 2012-06-13 2013-06-10 IN2014DN09346A (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12171839 2012-06-13
PCT/EP2013/061890 WO2013186159A1 (en) 2012-06-13 2013-06-10 New diazaspirocycloalkane and azaspirocycloalkane

Publications (1)

Publication Number Publication Date
IN2014DN09346A true IN2014DN09346A (el) 2015-07-17

Family

ID=48692428

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9346DEN2014 IN2014DN09346A (el) 2012-06-13 2013-06-10

Country Status (35)

Country Link
US (3) US9493486B2 (el)
EP (1) EP2861566B1 (el)
JP (1) JP6258928B2 (el)
KR (1) KR20150023373A (el)
CN (1) CN104364239B (el)
AR (1) AR091416A1 (el)
AU (1) AU2013276617B9 (el)
BR (1) BR112014030473A2 (el)
CA (1) CA2872213A1 (el)
CL (1) CL2014003136A1 (el)
CO (1) CO7121325A2 (el)
CR (1) CR20140501A (el)
CY (1) CY1118860T1 (el)
DK (1) DK2861566T3 (el)
EA (1) EA201492223A1 (el)
ES (1) ES2618703T3 (el)
HK (1) HK1202545A1 (el)
HR (1) HRP20161774T1 (el)
HU (1) HUE030526T2 (el)
IL (1) IL235826A (el)
IN (1) IN2014DN09346A (el)
LT (1) LT2861566T (el)
MA (1) MA37756B1 (el)
MX (1) MX358310B (el)
MY (1) MY180688A (el)
NZ (1) NZ702334A (el)
PE (1) PE20150230A1 (el)
PH (1) PH12014502697A1 (el)
PL (1) PL2861566T3 (el)
PT (1) PT2861566T (el)
RS (1) RS55717B1 (el)
SG (1) SG11201407534PA (el)
SI (1) SI2861566T1 (el)
TW (1) TWI633087B (el)
WO (1) WO2013186159A1 (el)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
IN2015DN00960A (el) * 2012-09-25 2015-06-12 Hoffmann La Roche
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
BR112015014372A8 (pt) 2012-12-19 2019-10-29 Novartis Ag inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
AR095328A1 (es) 2013-03-15 2015-10-07 Biogen Idec Inc Agentes de modulación de s1p y/o atx
US10196369B2 (en) * 2013-09-26 2019-02-05 Sanford Burnham Prebys Medical Discovery Institute Spirocyclic EBI2 modulators
EP3071561B1 (en) 2013-11-22 2021-03-24 Sabre Therapeutics LLC Autotaxin inhibitor compounds
PE20160845A1 (es) * 2013-11-26 2016-09-10 Hoffmann La Roche Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3119782B1 (en) * 2014-03-17 2018-01-31 reMynd NV 2,7-diazaspiro[3.5]nonane compounds
WO2015144605A1 (en) * 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MX2016010675A (es) 2014-03-26 2016-11-10 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
AP2016009496A0 (en) 2014-04-04 2016-10-31 X-Rx Inc Substituted spirocydic inhibitors of autotaxin
US10144732B2 (en) 2014-06-06 2018-12-04 Biogen Ma Inc. ATX modulating agents
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
CN104530046B (zh) * 2014-12-10 2016-08-24 广东东阳光药业有限公司 二氮杂螺类化合物及其在药物中的应用
CA2974311A1 (en) * 2015-01-20 2016-07-28 Novartis Ag Pet imaging agents
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CN106146483A (zh) * 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
BR122023011445B1 (pt) 2015-05-27 2024-02-27 Sabre Therapeutics Llc Inibidores de autotaxina e usos dos mesmos
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
PE20180479A1 (es) 2015-09-04 2018-03-07 Hoffmann La Roche Nuevos derivados de fenoximetilo
RU2018114289A (ru) 2015-09-24 2019-10-24 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов аутотаксина (atx)
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
MA42919A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
RU2724899C2 (ru) 2015-09-24 2020-06-26 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве дуальных ингибиторов atx/ca
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
CN108456208B (zh) * 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
CN110392679B (zh) * 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
US10961242B2 (en) 2017-05-17 2021-03-30 Legochem Biosciences, Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
ES2933184T3 (es) 2017-11-01 2023-02-02 Bristol Myers Squibb Co Compuestos espirocíclicos como moduladores del receptor farnesoide X
EP3704106B1 (en) 2017-11-01 2023-04-12 Bristol-Myers Squibb Company Alkene compounds as farnesoid x receptor modulators
KR20200081435A (ko) 2017-11-01 2020-07-07 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물
EP3704113B1 (en) 2017-11-01 2023-10-11 Bristol-Myers Squibb Company Bridged bicyclic compounds as farnesoid x receptor modulators
WO2019089665A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Alkene spirocyclic compounds as farnesoid x receptor modulators
UY37957A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
BR112020008834A2 (pt) 2017-11-02 2020-12-22 Calico Life Sciences Llc Moduladores da via de estresse integrada
EP3743425A1 (en) * 2018-01-23 2020-12-02 Bristol-Myers Squibb Company 2,8-diacyl-2,8-diazaspiro[5.5]undecane compounds useful as immunomodulators
WO2020119896A1 (en) * 2018-12-11 2020-06-18 F. Hoffmann-La Roche Ag Heterocyclic inhibitors of atx
CN113412113A (zh) * 2018-12-11 2021-09-17 豪夫迈·罗氏有限公司 氨基嗪酰胺
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
SG11202108798XA (en) 2019-02-15 2021-09-29 Bristol Myers Squibb Co Substituted amide compounds useful as farnesoid x receptor modulators
JP2022116370A (ja) * 2019-06-13 2022-08-10 アグロカネショウ株式会社 新規な１－ベンジルアミン誘導体及びこれを有効成分とする農園芸用薬剤
TW202211917A (zh) * 2020-08-21 2022-04-01 南韓商治納輔醫藥科技有限公司 對前列腺素e2受體具有抑制活性的新穎化合物及其用途
EP4274572A1 (en) * 2021-01-05 2023-11-15 Zydus Lifesciences Limited Novel inhibitors of autotaxin

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1252898B (de) * 1965-06-12 1967-10-26 Bayer Ag Verfahren zur Herstellung von Copolymerisaten des Trioxans
US5240928A (en) 1989-07-03 1993-08-31 Merck & Co., Inc. Substituted quinazolinones as angiotensin II antagonists
DE3930262A1 (de) * 1989-09-11 1991-03-21 Thomae Gmbh Dr K Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CA2037630C (en) 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
US5470975A (en) 1990-10-16 1995-11-28 E.R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
US5290780A (en) 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5238942A (en) 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US5202322A (en) 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
US5532243A (en) 1992-02-14 1996-07-02 The Dupont Merck Pharmaceutical Company Antipsychotic nitrogen-containing bicyclic compounds
US5358951A (en) 1993-04-23 1994-10-25 American Cyanamid Company Angiotensin II receptor blocking 2, 3, 6 substituted quinazolinones
DE4407047A1 (de) 1994-03-03 1995-09-07 Merck Patent Gmbh Acetamide
US20010016657A1 (en) 1997-03-18 2001-08-23 Smithkline Beecham P.L.C. Substituted isoquinoline derivatives and their use as anticonvulsants
JP3613179B2 (ja) * 1998-02-04 2005-01-26 萬有製薬株式会社 Ｎ−アシル環状アミン誘導体
JP2001039950A (ja) * 1999-07-30 2001-02-13 Banyu Pharmaceut Co Ltd Ｎ−アシル環状アミン誘導体
DE60005545D1 (de) * 1999-10-27 2003-10-30 Millennium Pharm Inc Pyridyl enthaltende spirocyclische verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation
CA2440803A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
WO2003086288A2 (en) 2002-04-12 2003-10-23 Merck & Co., Inc. Bicyclic amides
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
WO2005023762A1 (en) 2003-09-04 2005-03-17 Abbott Laboratories Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
SE0302811D0 (sv) * 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
US7226951B2 (en) 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
AU2005219438B2 (en) 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
DE602005004144T2 (de) 2004-06-09 2009-01-29 F. Hoffmann-La Roche Ag Octahydropyrroloä3,4-cüpyrrolderivate und deren verwendung als antivirale mittel
CN101035773B (zh) 2004-08-10 2012-06-06 詹森药业有限公司 抑制hiv的1,2,4-三嗪-6-酮衍生物
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
BRPI0610433A2 (pt) 2005-04-28 2010-11-23 Wyeth Corp forma polimórfica ii de tanaproget, processos para preparar a mesma, e para preparar forma micronizada de um composto, composição farmacêutica, método de preparação de uma composição farmacêutica, e, uso da forma polimórfica ii de tanaproget ou da forma micronizada
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
TW200800999A (en) * 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
DK1942108T3 (da) * 2005-10-28 2013-12-09 Ono Pharmaceutical Co Forbindelse indeholdende basisk gruppe samt anvendelse deraf
PL1961744T3 (pl) * 2005-11-18 2013-09-30 Ono Pharmaceutical Co Związek zawierający grupę zasadową oraz jego zastosowanie
US20070208001A1 (en) * 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
JP2008031064A (ja) 2006-07-27 2008-02-14 Astellas Pharma Inc ジアシルピペラジン誘導体
JP5256202B2 (ja) 2006-09-11 2013-08-07 エム・エス・ディー・オス・ベー・フェー キナゾリノンおよびイソキノリノンアセトアミド誘導体
JP2010503675A (ja) * 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛、糖尿病および脂質代謝の障害の治療に有用なスピロ縮合アゼチジン誘導体
US8735411B2 (en) * 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
EP2097388B1 (en) 2006-11-15 2011-09-07 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
EP2142520A1 (en) 2007-03-29 2010-01-13 F. Hoffmann-Roche AG Non-nucleoside reverse transcriptase inhibitors
CL2008001002A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
JP2010524987A (ja) 2007-04-27 2010-07-22 サノフィ−アベンティス ２−ヘテロアリール−ピロロ［３，４−ｃ］ピロール誘導体及びｓｃｄ阻害剤としてのそれらの使用
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
PE20091017A1 (es) 2007-10-31 2009-07-16 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
JP2009161449A (ja) * 2007-12-28 2009-07-23 Lion Corp Ｐｐａｒ活性促進剤並びに美容用飲食品、皮膚外用剤及び医薬
US20110071129A1 (en) * 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
US8673917B2 (en) 2008-09-09 2014-03-18 Sanofi 2-heteroaryl-pyrrolo [3,4-C]pyrrole derivatives, and use thereof as SCD inhibitors
TW201020247A (en) * 2008-11-06 2010-06-01 Gruenenthal Gmbh Substituierte disulfonamide
WO2010055006A1 (en) * 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Naphthylacetic acids used as crth2 antagonists or partial agonists
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
SG171809A1 (en) 2008-12-01 2011-07-28 Merck Patent Gmbh 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer
TW201035102A (en) * 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
TW201038572A (en) * 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
US8822476B2 (en) * 2009-04-02 2014-09-02 Merck Patent Gmbh Piperidine and piperazine derivatives as autotaxin inhibitors
WO2010112124A1 (en) 2009-04-02 2010-10-07 Merck Patent Gmbh Autotaxin inhibitors
EP2414327B1 (de) 2009-04-02 2014-11-19 Merck Patent GmbH Heterocyclische verbindungen als autotaxin-inhibitoren
FR2945534B1 (fr) 2009-05-12 2012-11-16 Sanofi Aventis DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
CA2763099A1 (en) * 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
US20120083476A1 (en) * 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
DE102009033392A1 (de) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
US8592402B2 (en) 2009-08-04 2013-11-26 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
IN2012DN05233A (el) 2010-01-07 2015-10-23 Du Pont
WO2011115813A1 (en) * 2010-03-18 2011-09-22 Abbott Laboratories Lactam acetamides as calcium channel blockers
ES2557895T3 (es) * 2010-03-19 2016-01-29 Pfizer Inc Derivados de 2,3-dihidro-1H-inden-1-il-2,7-diazaespiro[3.6]nonano y su uso como antagonistas o agonistas inversos del receptor de grelina
ES2562183T3 (es) 2010-03-26 2016-03-02 Merck Patent Gmbh Benzonaftiridinaminas como inhibidores de la autotaxina
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
EP2575794A2 (en) 2010-06-04 2013-04-10 B.S.R.C. "Alexander Fleming" Autotaxin pathway modulation and uses thereof
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
EP2606031B1 (en) 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
CN103189378B (zh) 2010-09-02 2016-03-02 默克专利股份公司 作为lpa受体拮抗剂的吡唑并吡啶酮衍生物
JP2014503528A (ja) 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
EP2714680B1 (en) 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
ES2609579T3 (es) * 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
WO2013065712A1 (ja) * 2011-10-31 2013-05-10 東レ株式会社 ジアザスピロウレア誘導体及びその医薬用途
US8809552B2 (en) * 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
WO2013079223A1 (en) 2011-12-02 2013-06-06 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rorϒ, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚ｏ－甲基轉移酶活性抑制化合物
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
SG11201500342PA (en) 2012-07-27 2015-02-27 Biogen Ma Inc Compounds that are s1p modulating agents and/or atx modulating agents
EA028364B1 (ru) 2012-07-27 2017-11-30 Биоген Айдек Ма Инк. Аутотаксин-модулирующие соединения
LT2900269T (lt) 2012-09-25 2018-11-12 Bayer Pharma Aktiengesellschaft Regorafenibo ir acetilsalicilo rūgšties derinys kolorektalinio vėžio gydymui
IN2015DN00960A (el) 2012-09-25 2015-06-12 Hoffmann La Roche
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
FR2996608B1 (fr) 2012-10-05 2024-05-10 Turbomeca Couvercle de compresseur centrifuge, assemblage de couvercle et de compresseur centrifuge, et turbomachine comportant un tel assemblage
PL2912019T3 (pl) 2012-10-25 2021-11-02 Tetra Discovery Partners Llc Heteroarylowe inhibitory pde4
US20160002247A1 (en) 2013-03-01 2016-01-07 The University Of Tokyo 8-substituted imidazopyrimidinone derivative having autotaxin inhibitory activity
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
TWI635087B (zh) 2013-03-12 2018-09-11 艾伯維有限公司 四環布羅莫域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑
US20160151369A1 (en) 2013-03-12 2016-06-02 Acucela Inc. Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders
AR095328A1 (es) 2013-03-15 2015-10-07 Biogen Idec Inc Agentes de modulación de s1p y/o atx
SG11201600241RA (en) 2013-07-18 2016-02-26 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
DK3057959T3 (en) 2013-10-17 2018-06-06 Vertex Pharma INHIBITORS FOR DNA PK
EP3071561B1 (en) 2013-11-22 2021-03-24 Sabre Therapeutics LLC Autotaxin inhibitor compounds
AR098475A1 (es) 2013-11-26 2016-06-01 Bayer Cropscience Ag Compuestos pesticidas y usos
PE20160845A1 (es) 2013-11-26 2016-09-10 Hoffmann La Roche Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo
PL3122732T3 (pl) 2014-03-26 2018-08-31 Basf Se Podstawione związki [1,2,4]triazolowe i imidazolowe jako fungicydy
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MX2016010675A (es) 2014-03-26 2016-11-10 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
WO2015144605A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
AP2016009496A0 (en) 2014-04-04 2016-10-31 X-Rx Inc Substituted spirocydic inhibitors of autotaxin
JP6564029B2 (ja) 2014-10-14 2019-08-21 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのジヒドロピロロピリジン阻害剤
JP6700291B2 (ja) 2015-02-15 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １−（ｈｅｔ）アリールスルホニル−（ピロリジン又はピペリジン）−２−カルボキサミド誘導体、及びｔｒｐａ１拮抗薬としてのそれらの使用
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CN104927727B (zh) 2015-07-06 2017-01-11 香山红叶建设有限公司 一种玻璃幕墙用结构密封胶及其制备方法
PL415078A1 (pl) 2015-09-04 2017-03-13 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
PE20180479A1 (es) 2015-09-04 2018-03-07 Hoffmann La Roche Nuevos derivados de fenoximetilo
RU2724899C2 (ru) 2015-09-24 2020-06-26 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве дуальных ингибиторов atx/ca
MA42919A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
RU2018114289A (ru) 2015-09-24 2019-10-24 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов аутотаксина (atx)
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
KR20180081809A (ko) 2015-11-25 2018-07-17 다나-파버 캔서 인스티튜트 인크. 2가 브로모도메인 억제제 및 그의 용도
JP6577051B2 (ja) 2015-12-01 2019-09-18 日本農薬株式会社 ３ｈ‐ピロロピリジン化合物若しくはそのｎ‐オキサイド、又はそれらの塩類及び該化合物を含有する農園芸用殺虫剤並びにその使用方法
WO2017139978A1 (zh) 2016-02-19 2017-08-24 吴伟东 手机app更新方法及系统
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
CN110392679B (zh) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物
NZ763766A (en) 2017-03-20 2023-07-28 Novo Nordisk Healthcare Ag Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators

Also Published As

Publication number Publication date
LT2861566T (lt) 2017-02-10
HK1202545A1 (en) 2015-10-02
US9493486B2 (en) 2016-11-15
DK2861566T3 (en) 2017-02-27
MA37756A1 (fr) 2018-01-31
NZ702334A (en) 2016-11-25
CN104364239B (zh) 2017-08-25
US10633384B2 (en) 2020-04-28
AU2013276617B9 (en) 2018-03-29
HUE030526T2 (en) 2017-05-29
KR20150023373A (ko) 2015-03-05
PL2861566T3 (pl) 2017-06-30
CO7121325A2 (es) 2014-11-20
SG11201407534PA (en) 2014-12-30
PH12014502697B1 (en) 2015-01-26
MX358310B (es) 2018-08-14
IL235826A (en) 2017-07-31
JP6258928B2 (ja) 2018-01-10
IL235826A0 (en) 2015-02-01
EA201492223A1 (ru) 2015-03-31
WO2013186159A1 (en) 2013-12-19
RS55717B1 (sr) 2017-07-31
EP2861566B1 (en) 2016-12-21
MY180688A (en) 2020-12-07
MX2014015049A (es) 2015-03-03
TWI633087B (zh) 2018-08-21
US20150099734A1 (en) 2015-04-09
BR112014030473A2 (pt) 2017-06-27
AU2013276617B2 (en) 2017-12-14
MA37756B1 (fr) 2018-09-28
PT2861566T (pt) 2017-02-08
CY1118860T1 (el) 2018-01-10
HRP20161774T1 (hr) 2017-02-24
CN104364239A (zh) 2015-02-18
EP2861566A1 (en) 2015-04-22
US20200207769A1 (en) 2020-07-02
CA2872213A1 (en) 2013-12-19
US20170029425A1 (en) 2017-02-02
AU2013276617A1 (en) 2014-11-20
PH12014502697A1 (en) 2015-01-26
AR091416A1 (es) 2015-02-04
ES2618703T3 (es) 2017-06-22
JP2015519380A (ja) 2015-07-09
TW201402545A (zh) 2014-01-16
CL2014003136A1 (es) 2015-02-27
PE20150230A1 (es) 2015-02-06
CR20140501A (es) 2014-12-02
SI2861566T1 (sl) 2017-03-31

Similar Documents

Publication Publication Date Title
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
IN2015DN00960A (el)
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX358376B (es) Nuevos derivados dihidroquinolina-2-ona.
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
PH12016500643A1 (en) New octahydro - cyclobuta [1,2-c;3,4-c`] dipyrrol -2- yl
MY169267A (en) New aryl-quinoline derivatives
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
EA201590887A1 (ru) Композиция
MX2012008141A (es) Compuestos y metodos.
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2015014470A (es) Analogos de combretastatina.
MX2013009388A (es) Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl).
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
MX346980B (es) Nuevos compuestos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona.
MX344429B (es) Nuevos compuestos de hexahidropirroloimidazolona.
MX2015009377A (es) Compuestos radiomarcados.
MX2014008856A (es) Derivados de imidazolilcetona como inhibidores de aldosterona sintasa.
PH12018500406A1 (en) Bicyclic compounds as atx inhibitors
IN2013DE03592A (el)